RE:RE:YouTube Interview That number included interest expense so it's closer to $10m free cash flow vs EBITDA. Plus there is opportunities for growth in the revenue number of which almost half will fall to free cash flow.
Also they have the potential partnership announcement on Kinlytic® urokinase for which there is no associated revenue and cash flow yet.
mercedesman wrote:
Thx.
picking up where you left off....
if a $10M EBITDA , using a conservative multiple for a profitable Biotech of just 10X ...
...that's a $100M market cap ( vs today's .. $47M
suggesting a share price of close to $1
After not insignificant insider buys this months, that was enough for me. I'm in for the 2 to 3 bagger.
the growth in revenue and profitability, if realized, will likely translate into a higher multiple - making a 4-5 bagger ( from here) quite possible!
Any US attention would be icing on the cake!
MM